Daniel T Barratt

List of Publications by Year
in descending order

27	874	623734 14	552781 26
papers	citations	h-index	g-index

27	27	27	1051
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	New pharmacological perspectives and therapeutic options for opioids: Differences matter. Anaesthesia and Intensive Care, 2022, , 0310057X2110638.	0.7	3
2	Toll-Like Receptor 4 in Pain: Bridging Molecules-to-Cells-to-Systems. Handbook of Experimental Pharmacology, 2022, , 1.	1.8	1
3	Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatmentâ€Refractory Depression. Clinical Pharmacology and Therapeutics, 2022, 112, 720-729.	4.7	5
4	Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. British Journal of Clinical Pharmacology, 2021, 87, 3901-3909.	2.4	13
5	Innate Immune and Neuronal Genetic Markers Are Highly Predictive of Postoperative Pain and Morphine Patient-Controlled Analgesia Requirements in Indian but Not Chinese or Malay Hysterectomy Patients. Pain Medicine, 2021, 22, 2648-2660.	1.9	4
6	Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele. Clinical and Translational Science, 2021, 14, 2521-2531.	3.1	6
7	Instability of Efavirenz Metabolites Identified During Method Development and Validation. Journal of Pharmaceutical Sciences, 2021, 110, 3362-3366.	3.3	1
8	No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation. Frontiers in Pharmacology, 2020, 10, 1686.	3.5	2
9	High and variable population prevalence of HLAâ€B*56:02 in indigenous Australians and relation to phenytoinâ€associated drug reaction with eosinophilia and systemic symptoms. British Journal of Clinical Pharmacology, 2019, 85, 2163-2169.	2.4	19
10	Is There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?. Therapeutic Drug Monitoring, 2019, 41, 528-532.	2.0	6
11	Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. Pharmacogenetics and Genomics, 2019, 29, 9-17.	1.5	9
12	CYP3A5*3 and ABCB1 61A>G Significantly Influence Doseâ€adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Postâ€Kidney Transplantation. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 320-326.	2.5	27
13	Pharmacogenomics in Papua New Guineans. Pharmacogenetics and Genomics, 2018, 28, 153-164.	1.5	6
14	Corticosterone Preexposure Increases NF-Î¹B Translocation and Sensitizes IL-1Î² Responses in BV2 Microglia-Like Cells. Frontiers in Immunology, 2018, 9, 3.	4.8	21
15	CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients. Clinical Pharmacokinetics, 2017, 56, 977-985.	3.5	16
16	Role of pharmacogenetics in personalised imatinib dosing. Translational Cancer Research, 2017, 6, S1541-S1557.	1.0	16
17	Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain. Pain, 2016, 157, 2458-2466.	4.2	26
18	Clinically Significant Interactions with Anti-addiction Agents. , 2016, , 565-577.		0

#	Article	IF	Citations
19	Impact ofCYP2C8*3polymorphism onin vitrometabolism of imatinib to N-desmethyl imatinib. Xenobiotica, 2016, 46, 278-287.	1.1	13
20	Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl. PLoS ONE, 2015, 10, e0137179.	2.5	20
21	Association of Innate Immune Single-Nucleotide Polymorphisms with the Electroencephalogram During Desflurane General Anaesthesia. Journal of Molecular Neuroscience, 2014, 52, 497-506.	2.3	17
22	Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. Pharmacogenetics and Genomics, 2014, 24, 185-194.	1.5	42
23	Pharmacogenomics of methadone maintenance treatment. Pharmacogenomics, 2014, 15, 1007-1027.	1.3	43
24	ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmacogenomics and Personalized Medicine, 2012, 5, 53.	0.7	39
25	Pharmacogenetics of Opioids. Clinical Pharmacology and Therapeutics, 2007, 81, 429-444.	4.7	298
26	ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clinical Pharmacology and Therapeutics, 2006, 80, 682-690.	4.7	132
27	Association between theDRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 323-331.	1.7	89